HAMBURG, Germany, May 11, 2011 /PRNewswire/ -- In response to the growing
interest in the sensitive blood-test for the detection of tumor-specific
DNA-molecules, Inostics GmbH (Hamburg, Germany) has founded a US subsidiary.
Inostics' non-invasive test based on the BEAMing-Technology is one of the
most sensitive methods available today for the detection of tumor specific
mutations and is already used in studies by pharmaceutical and biotechnology
companies. The founding of Inostics Inc. ensures faster processing of orders
for US customers. Inostics is also working on an approval of the test for
diagnostic use and for use in clinical studies which will be available
shortly.
Located within state-of-the-art-laboratories at The Science & Technology Park at Johns Hopkins in Baltimore, MD, Inostics Inc. will be headed by Dan Edelstein, MBA who has extensive experience from the Ludwig Center for Cancer Genetics and Therapeutics.
About Inostics:
Inostics GmbH is a biotech-company working in the field of cancer molecular genetics. At present, Inostics GmbH serves as a contract research organization for pharmaceutical companies and supports the development of new oncology drugs. Inostics' field of expertise is the highly sensitive detection of tumor-specific genetic changes, such as gene mutations, in plasma/serum and tissues samples. Inostics was founded in 2008 in Hamburg, by Indivumed GmbH, and scientists of the Johns Hopkins University in Baltimore.
Advertisement
Located within state-of-the-art-laboratories at The Science & Technology Park at Johns Hopkins in Baltimore, MD, Inostics Inc. will be headed by Dan Edelstein, MBA who has extensive experience from the Ludwig Center for Cancer Genetics and Therapeutics.
Advertisement
About Inostics:
Inostics GmbH is a biotech-company working in the field of cancer molecular genetics. At present, Inostics GmbH serves as a contract research organization for pharmaceutical companies and supports the development of new oncology drugs. Inostics' field of expertise is the highly sensitive detection of tumor-specific genetic changes, such as gene mutations, in plasma/serum and tissues samples. Inostics was founded in 2008 in Hamburg, by Indivumed GmbH, and scientists of the Johns Hopkins University in Baltimore.
For further information please visit http://www.inostics.com or write at
[email protected].
Germany: USA:
Inostics GmbH Inostics Inc.
Contact: Frank Diehl, Ph.D. Contact: Dan Edelstein, MBA
Centrum fuer Innovative Medizin Science & Technology Park at Johns
Hopkins
Falkenried 88 855 N. Wolfe Street, Suite 631
D-20251 Hamburg, Germany Baltimore, MD 21205, US
Tel.: +49(0)40-413383-90 Tel.: +1-443-759-8650
Fax: +49(0)40-413383-99 Fax: +1-443-455-1636
Email: [email protected] Email: [email protected]
SOURCE Inostics GmbH